Clinical assessment of immune-related adverse events


Por: Sosa, A, Cadena, EL, Olive, CS, Karachaliou, N and Rosell, R

Publicada: 30 mar 2018
Categoría: Oncology

Resumen:
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across diverse trials. Adverse events of an immune nature associated with these agents frequently affect the skin, colon, endocrine glands, lungs and liver. Most of these effects are mild and can be managed through transient immunosuppression with corticosteroids, but high-grade events often require hospitalization and specialized treatment. However, since immunotherapy is recent, physicians with clinical experience in the diagnosis and management of immune toxicities are frequently those who actively participated in trials, but many practicing oncologists are still not familiarized with the assessment of these events. This review focuses on the incidence, diagnostic assessment and recommended management of the most relevant immune-related adverse events.

Filiaciones:
Sosa, A:
 Hosp Univ Sagrat Cor, Dept Med Oncol, Viladomat 288, Barcelona 08029, Spain

Cadena, EL:
 Hosp Univ Sagrat Cor, Dept Pneumonol, Barcelona, Spain

Olive, CS:
 Hosp Univ Sagrat Cor, Dept Radiol, Barcelona, Spain

Karachaliou, N:
 Hosp Univ Sagrat Cor, Dept Med Oncol, Viladomat 288, Barcelona 08029, Spain

 Dr Rosell Oncol Inst, Dept Med Oncol, Barcelona, Spain

:
 Dr Rosell Oncol Inst, Dept Med Oncol, Barcelona, Spain

 Inst Invest Ciencies Germans & Trias Pujol, Campus Can Ruti, Badalona, Spain
ISSN: 17588340





Therapeutic Advances in Medical Oncology
Editorial
SAGE Publications, 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 10 Número:
Páginas:
WOS Id: 000429016100001
ID de PubMed: 29623110
imagen gold, Green Published

MÉTRICAS